VC Tally: $1.2bn Invested So Far In 2016 Includes Savara, Corvidia

New biotechnology companies still are able to raise some fairly large Series A venture capital rounds, contributing to a whopping $1.2bn in VC investment for drug developers during the first two months of 2016, but most startups and early-stage firms still are moving along at a pretty standard fundraising pace.

Prime examples: Savara Pharmaceuticals raised a $20m Series C round to move AeroVanc for lung infections in people with cystic fibrosis into Phase III, and Corvidia Therapeutics launched with a $26m Series A round to take a cardiovascular therapy from AstraZeneca PLC into the clinic. At the same time, a new investor and some prior eFFECTOR Therapeutics Inc